Montelukast Für Kinder Im Alter Von 6 Bis 14 Jahren Eurogenerics (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle and inflammatory cells. By preventing leukotrienes from binding, it reduces bronchoconstriction, mucus production, and vascular leakage, leading to improved airway patency and decreased allergic inflammation.

The appropriate dose of Montelukast Für Kinder is determined by the prescribing clinician based on the child’s age, weight, and specific condition being treated. Healthcare professionals follow approved pediatric dosing guidelines and adjust the regimen as needed for optimal therapeutic effect.

Safety data for Montelukast in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the child outweighs any possible risk to the mother. Pregnant or nursing mothers must discuss use with their healthcare provider before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting beta‑agonists. It is particularly useful for patients with allergic components or exercise‑induced symptoms, whereas inhaled steroids directly target airway inflammation. Choice of therapy depends on individual disease profile and physician assessment.

Montelukast tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its potency throughout the shelf life.

Montelukast is taken orally, usually as a chewable tablet or oral granule that can be mixed with a small amount of soft food or liquid. The dose is administered once daily, preferably in the evening, as directed by the prescribing clinician.

Serious risks, though rare, include severe allergic reactions such as rash, angioedema, or anaphylaxis, and neuropsychiatric events like mood changes, agitation, or suicidal thoughts. Any signs of these reactions require immediate medical evaluation and possible discontinuation of therapy.

Montelukast should not be used in children with known hypersensitivity to the drug or any of its excipients. It is also not appropriate for acute asthma attacks, where a rapid‑acting bronchodilator is required. Clinicians must evaluate each patient’s medical history before prescribing.